Successful first phase of clinical trials of Russian anti-cancer drug

Russia – The Russian anti-tumor drug “AntionkoRAN-M” has successfully passed the first phase of clinical trials.

The developers of the Russian gene therapy drug against cancer AntionkoRAN-M have completed the first phase of clinical trials, confirming its safety, the press service of the Russian platform “National Technology Initiative” reported.

It is noteworthy that “AntionkoRAN-M” is the first Russian non-viral gene therapy drug against cancer, which has received a license from the Ministry of Health for clinical trials. The tests involved 13 patients aged 30 to 78 years. The drug was developed by the company “Russian Biotechnology”.

“The main goal of the first phase of clinical trials of the drug is to confirm the safety of the drug for patients. During the study, no serious adverse events associated with the use of AntionkoRAN-M were identified in any of the patients. In addition, a response to treatment was obtained in many patients, despite the fact that they had undergone a large number of different treatment programs and exhausted all possible treatment methods,” said Maxim Koksharov, founder of Russian Biotech.

The active part of the Phase I studies lasted for two years. During this time, the drug developers confirmed its safety, selected the necessary dose and sequence of treatment, evaluated the distribution of the drug in the human body, and diagnosed patients with tumors such as skin cancer, breast cancer, chondrosarcoma, and others.

“All of these patient classifications require new types of treatments because doctors have a limited number of tools to combat them,” Koksharov added. “We have two more phases of research before we can bring the drug to the market.”

In the next stages of testing, scientists will evaluate the effectiveness of the drug in combating different types of tumors, as well as its effect on a wider group of patients. The company has sent a package of documents to the Russian Ministry of Health to obtain permission to conduct phase II clinical trials.

Source: TASS